Brian M. Olson

1.2k total citations
27 papers, 590 citations indexed

About

Brian M. Olson is a scholar working on Oncology, Immunology and Molecular Biology. According to data from OpenAlex, Brian M. Olson has authored 27 papers receiving a total of 590 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Oncology, 15 papers in Immunology and 11 papers in Molecular Biology. Recurrent topics in Brian M. Olson's work include Immunotherapy and Immune Responses (12 papers), Cancer Immunotherapy and Biomarkers (11 papers) and Cancer Research and Treatments (4 papers). Brian M. Olson is often cited by papers focused on Immunotherapy and Immune Responses (12 papers), Cancer Immunotherapy and Biomarkers (11 papers) and Cancer Research and Treatments (4 papers). Brian M. Olson collaborates with scholars based in United States, United Kingdom and China. Brian M. Olson's co-authors include Akash Patnaik, Edison T. Liu, Yadi Li, Yu Lin, Douglas G. McNeel, Jordan T. Becker, William J. Burlingham, Dario A.A. Vignali, Ewa Jankowska−Gan and Laura E. Johnson and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and The Journal of Immunology.

In The Last Decade

Brian M. Olson

25 papers receiving 584 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Brian M. Olson United States 9 321 308 167 95 67 27 590
Micaela Morgado United States 9 366 1.1× 252 0.8× 169 1.0× 126 1.3× 61 0.9× 12 641
Maria M. Martins Brazil 4 492 1.5× 443 1.4× 164 1.0× 67 0.7× 67 1.0× 11 738
Tom J. Harryvan Netherlands 10 449 1.4× 340 1.1× 242 1.4× 62 0.7× 46 0.7× 15 642
Tomáš Brtnický Czechia 8 364 1.1× 485 1.6× 145 0.9× 57 0.6× 69 1.0× 13 688
Moses Donkor United States 8 397 1.2× 542 1.8× 226 1.4× 73 0.8× 27 0.4× 12 807
Greg Motz United States 5 590 1.8× 653 2.1× 232 1.4× 92 1.0× 109 1.6× 10 947
James M. Leatherman United States 13 461 1.4× 443 1.4× 271 1.6× 84 0.9× 35 0.5× 26 814
Hans Anton Schloesser Germany 5 247 0.8× 168 0.5× 136 0.8× 89 0.9× 61 0.9× 11 438
Haofan Jin China 13 345 1.1× 361 1.2× 176 1.1× 57 0.6× 43 0.6× 25 681
Houssein Abdul Sater United States 11 373 1.2× 298 1.0× 122 0.7× 81 0.9× 21 0.3× 33 513

Countries citing papers authored by Brian M. Olson

Since Specialization
Citations

This map shows the geographic impact of Brian M. Olson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Brian M. Olson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Brian M. Olson more than expected).

Fields of papers citing papers by Brian M. Olson

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Brian M. Olson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Brian M. Olson. The network helps show where Brian M. Olson may publish in the future.

Co-authorship network of co-authors of Brian M. Olson

This figure shows the co-authorship network connecting the top 25 collaborators of Brian M. Olson. A scholar is included among the top collaborators of Brian M. Olson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Brian M. Olson. Brian M. Olson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Olson, Brian M., et al.. (2023). BET Inhibition Sensitizes Immunologically Cold Rb-Deficient Prostate Cancer to Immune Checkpoint Blockade. Molecular Cancer Therapeutics. 22(6). 751–764. 3 indexed citations
2.
Akce, Mehmet, Batoul Farran, Jeffrey M. Switchenko, et al.. (2023). Phase II trial of nivolumab and metformin in patients with treatment-refractory microsatellite stable metastatic colorectal cancer. Journal for ImmunoTherapy of Cancer. 11(10). e007235–e007235. 24 indexed citations
3.
Ruffin, Ayana T., Brian M. Olson, Crystal Mallow, et al.. (2023). 629 Neoadjuvant SEMA4D inhibitor pepinemab combination with nivolumab increases crosstalk between B cell and CD26hi T cell in patients with resectable stage III melanoma. SHILAP Revista de lepidopterología. A718–A718. 1 indexed citations
4.
Yarchoan, Mark, Subir Goyal, Yuan Liu, et al.. (2022). Combined MEK/PD-L1 Inhibition Alters Peripheral Cytokines and Lymphocyte Populations Correlating with Improved Clinical Outcomes in Advanced Biliary Tract Cancer. Clinical Cancer Research. 28(19). 4336–4345. 10 indexed citations
5.
Farran, Batoul, Jeffrey M. Switchenko, Lana Khalil, et al.. (2022). Abstract 3482: Correlative analysis of metformin and nivolumab combination in treatment-refractory microsatellite stable (MSS) metastatic colorectal cancer (mCRC). Cancer Research. 82(12_Supplement). 3482–3482. 1 indexed citations
6.
Zaidi, Mohammad Y., Brian M. Olson, Matthew R. Farren, et al.. (2020). Heat Shock Protein-90 Inhibition Alters Activation of Pancreatic Stellate Cells and Enhances the Efficacy of PD-1 Blockade in Pancreatic Cancer. Molecular Cancer Therapeutics. 20(1). 150–160. 39 indexed citations
7.
Sullivan, Jeremy A., David Al‐Adra, Brian M. Olson, Douglas G. McNeel, & William J. Burlingham. (2020). Infectious Tolerance as Seen With 2020 Vision: The Role of IL-35 and Extracellular Vesicles. Frontiers in Immunology. 11. 1867–1867. 8 indexed citations
8.
Lowe, Michael, Brian M. Olson, Anthony P. Martinez, et al.. (2020). Integrated biomarker study of neoadjuvant pepinemab and nivolumab in patients with resectable metastatic melanoma.. Journal of Clinical Oncology. 38(15_suppl). 10061–10061. 2 indexed citations
9.
Olson, Brian M. & Akash Patnaik. (2018). Utilizing precision medicine to modulate the prostate tumor microenvironment and enhance immunotherapy. Urologic Oncology Seminars and Original Investigations. 37(8). 535–542. 2 indexed citations
10.
Olson, Brian M., Yadi Li, Yu Lin, Edison T. Liu, & Akash Patnaik. (2018). Mouse Models for Cancer Immunotherapy Research. Cancer Discovery. 8(11). 1358–1365. 289 indexed citations
11.
Johnson, Laura E., Brian M. Olson, & Douglas G. McNeel. (2017). Pretreatment antigen-specific immunity and regulation - association with subsequent immune response to anti-tumor DNA vaccination. Journal for ImmunoTherapy of Cancer. 5(1). 56–56. 11 indexed citations
12.
Ellis, Leigh, Sheng‐Yu Ku, Gissou Azabdaftari, et al.. (2016). Generation of a C57BL/6MYC-Driven Mouse Model and Cell Line of Prostate Cancer. The Prostate. 76(13). 1192–1202. 16 indexed citations
13.
McNeel, Douglas G., Jordan T. Becker, Jens C. Eickhoff, et al.. (2014). Real-Time Immune Monitoring to Guide Plasmid DNA Vaccination Schedule Targeting Prostatic Acid Phosphatase in Patients with Castration-Resistant Prostate Cancer. Clinical Cancer Research. 20(14). 3692–3704. 48 indexed citations
14.
McNeel, Douglas G., Jordan T. Becker, Jens C. Eickhoff, et al.. (2013). Long-term immune responses elicited by a DNA vaccine encoding prostatic acid phosphatase (PAP) in patients with nonmetastatic castrate-resistant prostate cancer.. Journal of Clinical Oncology. 31(6_suppl). 135–135. 2 indexed citations
15.
McNeel, Douglas G., Jordan T. Becker, Laura E. Johnson, & Brian M. Olson. (2012). DNA Vaccines for Prostate Cancer. Current Cancer Therapy Reviews. 8(4). 245–253. 8 indexed citations
16.
McNeel, Douglas G. & Brian M. Olson. (2011). Sipuleucel-T: immunotherapy for advanced prostate cancer. Research and Reports in Urology. Volume 3. 49–60. 1 indexed citations
17.
McNeel, Douglas G. & Brian M. Olson. (2011). Sipuleucel-T: immunotherapy for advanced prostate cancer. PubMed. 3. 49–49. 7 indexed citations
18.
Bergendahl, Veit, et al.. (2009). Studying the Salt Dependence of the Binding of σ70 and σ32 to Core RNA Polymerase Using Luminescence Resonance Energy Transfer. PLoS ONE. 4(8). e6490–e6490. 11 indexed citations
19.
Olson, Brian M., Daniel C. Malone, & Edward P. Armstrong. (2001). Modeling the cost-effectiveness of doubling atorvastatin's dose versus adding niacin ER. 36(10). 730–746. 2 indexed citations
20.
Olson, Brian M., et al.. (1993). Strength Changes of the Quadriceps and Alterations in Vertical Leap Measurements after 6 Weeks of Training on the Shuttle 2000. Isokinetics and Exercise Science. 3(1). 57–62. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Micaela Morgado Breakdown of academic impact, for papers by Maria M. Martins Breakdown of academic impact, for papers by Tom J. Harryvan Breakdown of academic impact, for papers by Tomáš Brtnický Breakdown of academic impact, for papers by Moses Donkor Breakdown of academic impact, for papers by Greg Motz Breakdown of academic impact, for papers by James M. Leatherman Breakdown of academic impact, for papers by Hans Anton Schloesser Breakdown of academic impact, for papers by Haofan Jin Breakdown of academic impact, for papers by Houssein Abdul Sater
Rankless by CCL
2026